Computer-aided tool to predict outcomes after simultaneous colorectal and liver surgery
Official title: A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Performance Improvement From Computer-aided Tool for the Prognostic Prediction of Colorectal Liver Metastases
Run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT07027605 · Data updated 2026-11-12
This project will test a web-based computer tool that helps doctors predict 1-, 3-, and 5-year recurrence and survival for adults with colorectal cancer who had liver metastases removed at the same time as their primary tumor.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 166 (estimated) |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | September 20, 2025 |
| Study ends | September 25, 2025 |
| Registry record updated | August 19, 2025 |
| Trial ID | NCT07027605 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed colorectal adenocarcinoma liver metastases who underwent simultaneous resection of the primary tumor and liver lesions with adequate follow-up data are the cases used in this work.
✕Probably not a fit
Patients with other active malignancies, insufficient or missing follow-up data, or who did not have simultaneous colorectal and liver resection are unlikely to benefit from this tool.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multi-reader, multi-case observational study uses 166 retrospective patient cases to compare clinician predictions with and without a web-based Random Forest prognostic tool that integrates demographic, clinical, laboratory, and genetic data. Twelve physicians will independently estimate 1-, 3-, and 5-year recurrence and mortality risks for each case, with the two assessment rounds separated by a washout period. The primary analysis measures whether access to the tool improves accuracy of 3-year postoperative predictions. All cases are from patients who underwent simultaneous colorectal and liver resection at a single tertiary cancer center.
Why it matters
Potential benefit: If successful, the tool could give doctors more accurate personalized estimates of recurrence and survival after simultaneous resection, helping guide treatment choices and follow-up planning.
How similar studies have gone: Machine-learning prognostic models for CRLM have shown promising accuracy in prior publications, but few prior studies have used a multi-reader, multi-case design to test whether such tools actually improve clinician predictions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years old * confirmation of histologically diagnosed liver metastases of colorectal adenocarcinoma * receiving colorectal resection with simultaneous liver resection. Exclusion Criteria: * presence of other malignancies * absence of follow-up data * patients who were followed up postoperatively for less than 5 years and had no occurrences of death.
Where it's running
-
No. 17, South Panjiayuan, Chaoyang District, Beijing, Cancer Hospital, Chinese Academy of Medical Sciences, China
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Hong Zhao, MD — Cancer Hospital Chinese Academy of Medical Science
- Study coordinator: Hong Zhao, Md
- Email: zhaohong@cicams.ac.cn
- Phone: +8613381106850
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Detecting tumor DNA in small automated capillary blood samples from adults with colorectal cancer liver metastases.
This project will try whether tiny automated capillary (finger‑prick) blood samples can detect circulating tumor DNA in adults with colorectal cancer that has spread to the liver.
-
Using FOLFOX-HAIC to treat colorectal liver metastasis that can't be surgically removed
This study is testing if a new combination of chemotherapy and targeted treatments can help people with colorectal cancer that has spread to the liver and can't be surgically removed, so they can eventually have surgery and live longer.
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer
This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.
-
Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer
This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.
-
Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread
This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.